These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 12444552)
21. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058 [TBL] [Abstract][Full Text] [Related]
22. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Santoro M; Chiappetta G; Cerrato A; Salvatore D; Zhang L; Manzo G; Picone A; Portella G; Santelli G; Vecchio G; Fusco A Oncogene; 1996 Apr; 12(8):1821-6. PubMed ID: 8622903 [TBL] [Abstract][Full Text] [Related]
23. Concurrent overexpression of RET/PTC1 and TTF1 confers tumorigenicity to thyrocytes. Endo T; Kobayashi T Endocr Relat Cancer; 2013 Dec; 20(6):767-76. PubMed ID: 24014739 [TBL] [Abstract][Full Text] [Related]
24. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Russell JP; Powell DJ; Cunnane M; Greco A; Portella G; Santoro M; Fusco A; Rothstein JL Oncogene; 2000 Nov; 19(50):5729-35. PubMed ID: 11126359 [TBL] [Abstract][Full Text] [Related]
25. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Lanzi C; Cassinelli G; Cuccuru G; Zaffaroni N; Supino R; Vignati S; Zanchi C; Yamamoto M; Zunino F Cell Mol Life Sci; 2003 Jul; 60(7):1449-59. PubMed ID: 12943231 [TBL] [Abstract][Full Text] [Related]
26. Prevalence, significance, and biological behavior of ret/PTC1 associated papillary thyroid carcinoma. Cetta F J Clin Endocrinol Metab; 1997 May; 82(5):1650. PubMed ID: 9141569 [No Abstract] [Full Text] [Related]
27. A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. Sozzi G; Bongarzone I; Miozzo M; Borrello MG; Blutti MG; Pilotti S; Della Porta G; Pierotti MA Genes Chromosomes Cancer; 1994 Apr; 9(4):244-50. PubMed ID: 7519046 [TBL] [Abstract][Full Text] [Related]
28. [Oncogenes RET/PTC and mechanisms of their involvement in thyroid cancerogenesis]. Voskoboĭnyk LH Ukr Biokhim Zh (1999); 2009; 81(6):17-25. PubMed ID: 20387655 [TBL] [Abstract][Full Text] [Related]
29. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. Raouane M; Desmaele D; Gilbert-Sirieix M; Gueutin C; Zouhiri F; Bourgaux C; Lepeltier E; Gref R; Ben Salah R; Clayman G; Massaad-Massade L; Couvreur P J Med Chem; 2011 Jun; 54(12):4067-76. PubMed ID: 21561161 [TBL] [Abstract][Full Text] [Related]
30. Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol. Ali HM; Maksimenko A; Urbinati G; Chapuis H; Raouane M; Desmaële D; Yasuhiro H; Harashima H; Couvreur P; Massaad-Massade L Thyroid; 2014 Feb; 24(2):327-38. PubMed ID: 23885719 [TBL] [Abstract][Full Text] [Related]
31. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. La Perle KM; Jhiang SM; Capen CC Am J Pathol; 2000 Aug; 157(2):671-7. PubMed ID: 10934169 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative. Lanzi C; Cassinelli G; Pensa T; Cassinis M; Gambetta RA; Borrello MG; Menta E; Pierotti MA; Zunino F Int J Cancer; 2000 Feb; 85(3):384-90. PubMed ID: 10652431 [TBL] [Abstract][Full Text] [Related]
33. Thyroid-stimulating hormone promotes growth of thyroid carcinomas in transgenic mice with targeted expression of the ret/PTC1 oncogene. Sagartz JE; Jhiang SM; Tong Q; Capen CC Lab Invest; 1997 Mar; 76(3):307-18. PubMed ID: 9121114 [TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A. Bongarzone I; Monzini N; Borrello MG; Carcano C; Ferraresi G; Arighi E; Mondellini P; Della Porta G; Pierotti MA Mol Cell Biol; 1993 Jan; 13(1):358-66. PubMed ID: 7678053 [TBL] [Abstract][Full Text] [Related]
35. The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias. Leone V; Ferraro A; Schepis F; Federico A; Sepe R; Arra C; Langella C; Palma G; De Lorenzo C; Troncone G; Masciullo V; Scambia G; Fusco A; Pallante P Cancer Lett; 2015 Feb; 357(2):535-41. PubMed ID: 25497869 [TBL] [Abstract][Full Text] [Related]
36. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553 [TBL] [Abstract][Full Text] [Related]
37. [Genetic factors predisposing to the development of papillary thyroid cancer]. Puzianowska-Kuźnicka M; Pietrzak M Endokrynol Pol; 2005; 56(3):339-45. PubMed ID: 16350729 [TBL] [Abstract][Full Text] [Related]
38. Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice. Chen Y; Li YH; Chen XP; Gong LM; Zhang SP; Chang ZJ; Zhang XF; Fu XY; Liu L Cancer Res; 2005 Dec; 65(23):10838-46. PubMed ID: 16322230 [TBL] [Abstract][Full Text] [Related]